Gilead Sciences Valuation
| GILD Stock | MXN 1,892 79.51 4.39% |
At this time, the firm appears to be undervalued. Gilead Sciences retains a regular Real Value of 2098.89 per share. The prevalent price of the firm is 1892.4. Our model calculates the value of Gilead Sciences from evaluating the firm fundamentals such as Current Valuation of 2.55 T, return on equity of 0.22, and Return On Asset of 0.1 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Gilead Sciences' price fluctuation is very steady at this time. Calculation of the real value of Gilead Sciences is based on 3 months time horizon. Increasing Gilead Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Gilead Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gilead Stock. However, Gilead Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1892.4 | Real 2098.89 | Hype 1892.4 | Naive 1879.55 |
The intrinsic value of Gilead Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gilead Sciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gilead Sciences helps investors to forecast how Gilead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gilead Sciences more accurately as focusing exclusively on Gilead Sciences' fundamentals will not take into account other important factors: Gilead Sciences Total Value Analysis
Gilead Sciences is currently anticipated to have takeover price of 2.55 T with market capitalization of 2.01 T, debt of 25.18 B, and cash on hands of 29.01 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Gilead Sciences fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.55 T | 2.01 T | 25.18 B | 29.01 B |
Gilead Sciences Investor Information
About 84.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.7. Gilead Sciences recorded earning per share (EPS) of 68.39. The entity last dividend was issued on the 14th of March 2023. The firm had 2:1 split on the 28th of January 2013. Based on the key indicators related to Gilead Sciences' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Gilead Sciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Gilead Sciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gilead Sciences has an asset utilization ratio of 43.19 percent. This suggests that the Company is making 0.43 for each dollar of assets. An increasing asset utilization means that Gilead Sciences is more efficient with each dollar of assets it utilizes for everyday operations.Gilead Sciences Ownership Allocation
Gilead Sciences has a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Gilead Sciences Profitability Analysis
The company reported the revenue of 27.28 B. Net Income was 4.59 B with profit before overhead, payroll, taxes, and interest of 21.62 B.About Gilead Sciences Valuation
Our relative valuation model uses a comparative analysis of Gilead Sciences. We calculate exposure to Gilead Sciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gilead Sciences's related companies.Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD SCIENCES operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 11000 people.
8 Steps to conduct Gilead Sciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Gilead Sciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Gilead Sciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Gilead Sciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Gilead Sciences' revenue streams: Identify Gilead Sciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Gilead Sciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Gilead Sciences' growth potential: Evaluate Gilead Sciences' management, business model, and growth potential.
- Determine Gilead Sciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Gilead Sciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Gilead Stock Analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.